An investigation for investors in Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares over potential securities laws violations by Adamis Pharmaceuticals was announced and NASDAQ:ADMP stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 04/07/2015 --An investigation on behalf of investors of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares over potential securities laws violations by Adamis Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) concerning whether a series of statements by Adamis Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 27, 2015, Adamis Pharmaceuticals Corp announced that it had received a Complete Response Letter from the U.S. Food & Drug Administration ("FDA") regarding the Company's New Drug Application ("NDA") for its Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe, or the Epinephrine PFS, product, for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction.

According to Adamis Pharmaceuticals Corp on May 28, 2014, it submitted an NDA to the FDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act, as amended, for approval of the Epinephrine PFS product. The Epinephrine PFS delivers a premeasured dose of ephinephrine for the emergency treatment of anaphylaxis.

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) declined to as low as $3.56 per share on March 30, 2015.

On April 2, 2015, NASDAQ:ADMP shares closed at $3.84 per share, which is significantly below its current 52 week High of $7.26 per share.

Those who purchased shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com